Madrigal says it's 'well on the way' to potential NASH launch ahead of FDA decision: #JPM24

Nicole DeFeudis

Editor

SAN FRANCISCO — Madrigal Pharmaceuticals will be “ready to go” if the FDA grants its nonalcoholic steatohepatitis hopeful an accelerated approval in March, the company’s new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Madrigal says it's 'well on the way' to potential NASH launch ahead of FDA decision: #JPM24

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Madri­gal says it's 'well on the way' to po­ten­tial NASH launch ahead of FDA de­ci­sion: #JPM24

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Madrigal says it's 'well on the way' to potential NASH launch ahead of FDA decision: #JPM24